The exclusive licensing agreement gives HelferApp the exclusive rights for NovaVision’s diagnostic products and therapies provided directly to patients and medical professionals in Germany, Austria and Switzerland, according to a news release.
Vycor previously said in May that it planned to close NovaVision’s German office and evaluate a transition to a license model for the subsidiary in Europe. NovaVision will look to partner with regional companies to leverage its clinically supported vision therapies, as well.
HelferApp plans to drive the adoption of NovaVision’s NeuroEyeCoach saccadic training program, which recently demonstrated effectiveness in assisting patients who have a visual field deficit with their visual search tasks, according to the release.
Existing NovaVision patients currently treated by the company in the covered regions will be transferred to the HelferApp, while other European and international patients treated by the German office will be handled by NovaVision’s U.S. clinicians.
“We are delighted to be entering into a partnership with HelferApp, who we believe is the perfect partner to leverage our therapies and diagnostics more broadly into the German, Austrian and Swiss markets,” Vycor CEO Peter Zachariou said in the release. “This marks an encouraging first step in our strategy of entering into licensing agreements with strong regional partners”.